A New Medicine for Cancers with Specific DNA Repair Problems
Therapeutic Potential of a Novel MGMT-Dependent DNA Interstrand Crosslinking Agent in the Treatment of DNA Repair Deficient Cancer
This research explores a new medicine called KL-50 that targets cancers with specific DNA repair weaknesses, especially those that no longer respond to common treatments like temozolomide.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11169718 on NIH RePORTER |
What this research studies
Many cancers have problems with how they repair their DNA, which can be a weakness we can use to fight them. One important repair system involves a protein called MGMT, and when cancers lack MGMT, they are often more sensitive to certain chemotherapy drugs. However, some cancers become resistant to these drugs, even without MGMT, because of other repair issues. This project focuses on a new drug, KL-50, designed to specifically damage MGMT-deficient cancer cells in a way that overcomes this resistance. We aim to understand how KL-50 works and if it could be a more effective treatment for these challenging cancers.
Who could benefit from this research
Good fit: This research is relevant for patients with cancers that lack the MGMT protein and have developed resistance to standard alkylating chemotherapy drugs like temozolomide.
Not a fit: Patients whose tumors have normal MGMT function or do not have the specific DNA repair defects targeted by this agent would likely not benefit from this particular approach.
Why it matters
Potential benefit: If successful, this new medicine could offer a much-needed treatment option for patients whose cancers have become resistant to current therapies due to specific DNA repair defects.
How similar studies have performed: This project introduces a novel agent, KL-50, that has shown promise in preliminary work by overcoming resistance mechanisms seen with existing drugs like temozolomide.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Gueble, Susan E — Yale University
- Study coordinator: Gueble, Susan E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.